One important metric to look for in a stock is an 80 or higher Relative Strength Rating. CRISPR Therapeutics just hit that mark, with a jump from 78 to 85 Tuesday.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary RS Rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the top-performing stocks typically have an RS Rating of over 80 in the early stages of their moves.
CRISPR Therapeutics is working on a double bottom with a 55.88 entry. See if the stock can break out in heavy trading.
The company showed 0% EPS growth last quarter, while sales growth came in at 74%.
CRISPR Therapeutics holds the No. 138 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
